SC
BMRN icon

Stephens Consulting’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stephens Consulting’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13
Closed -$715 – 498
2025
Q2 		$715 Buy
+13
New +$766 ﹤0.01% 794

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Stephens Consulting's BMRN Position: Q3 2025 in Review

Stephens Consulting sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 13 shares — an estimated $715 sold.

Stephens Consulting first reported a position in BMRN in Q2 2025 and held it in 1 quarter. The position peaked at $715 in Q2 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Stephens Consulting reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 13 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $715.
  • Stephens Consulting first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Stephens Consulting's BioMarin Pharmaceuticals position peaked at $715 in Q2 2025.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.